All In Biotech

Drug Trial Radar · NCT04729907

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Apr 19, 2021

Primary completion

Jul 30, 2026

Study completion Jul 30, 2026

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jan 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study is an extension study and will enroll only those participants who have completed treatment in the parent study, 232SM203. The main goal of the study is to learn about the long-term safety of nusinersen. The main questions researchers want to answer are: * How many participants have adverse events and serious adverse events during the study? * How do the results of electrocardiograms (ECGs), vital signs, and laboratory tests including blood and urine tests change after treatment? * How many participants have a low platelet count after treatment? * How many participants had a change in the time it took for their heart to recharge between beats after treatment? * How does each participant's height and other measures of growth change after treatment? * How much do the results of neurological exams that check movement, reflexes, and brain function change after treatment? Researchers will also learn about the effect of nusinersen on mobility using various tests. They will study body movements, reflexes, balance, and coordination. They will also record if participants need help with breathing. The 232SM302 study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will receive their 1st dose of nusinersen in this study about 4 months after their final dose in the parent study. * Each participant will receive nusinersen once every 4 months during the treatment period. * Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back. * The treatment period will last for up to 64 months (1921 days). * There will be a follow-up safety period that lasts from 4 to 8 weeks. * In total, participants will have up to 19 study visits. Participants will stay in the study for close to 6 years.

Conditions

  • Muscular Atrophy, Spinal

Interventions

  • NusinersenDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 1921
  2. Change from Baseline in Growth ParametersTime frame: Up to Day 1921
  3. Number of Participants With Shifts from Baseline in Clinical Laboratory ParametersTime frame: Up to Day 1921
  4. Number of Participants With Shifts from Baseline in Electrocardiogram (ECG)Time frame: Up to Day 1921
  5. Number of Participants With Shifts from Baseline in Vital SignsTime frame: Up to Day 1921
  6. Change from Baseline in Activated Partial Thromboplastin Time (aPTT)Time frame: Up to Day 1921
  7. Change from Baseline in Prothrombin Time (PT)Time frame: Up to Day 1921
  8. Change from Baseline in International Normalized Ratio (INR)Time frame: Up to Day 1921
  9. Change from Baseline in Urine Total ProteinTime frame: Up to Day 1921
  10. Change from Baseline in Neurological Examination Outcomes for Participants ≤2 Years of AgeTime frame: Up to Day 1921
  11. Number of Participants with Change from Baseline in Neurological Examination Outcomes for Participants >2 Years of AgeTime frame: Up to Day 1921
  12. Percentage of Participants With a Postbaseline Platelet Count Below the Lower Limit of Normal on at least 2 Consecutive MeasurementsTime frame: Up to Day 1921
  13. Percentage of Participants With a Postbaseline Corrected QT Interval Using Fridericia's Formula (QTcF) of >500 millisecond (msec) and an Increase from Baseline to Any Postbaseline Timepoint in QTcF of >60 msecTime frame: Up toDay 1921

Locations

39 sites in 16 countries. Site status is shown where the registry gives one.

  • Stanford University Medical Center

    Sacramento, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Children's Medical Center

    Plano, Texas

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Brazil

  • Hospital das Clinicas - FMUSP

    São Paulo, Brazil

  • London Health Sciences Centre (LHSC) - Children's Hospital

    London, Ontario, Canada

  • Hospital Luis Calvo Mackenna

    Santiago, Chile

  • Clinica Las Condes

    Santiago, Chile

  • Clinica MEDS La Dehesa

    Santiago, Chile

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Guangzhou Woman and Children's Medical Center

    Guangzhou, Guangdong, China

  • The Children's Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Tallinn Children's Hospital

    Tallinn, Estonia

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH

    Giessen, Hesse, Germany

  • Fondazione Serena Onlus - Centro Clinico Nemo

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Kurume University Hospital

    Kurume-shi, Fukuoka, Japan

  • Hyogo Medical University Hospital

    Nishinomiya-shi, Hyōgo, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo-To, Japan

  • Saint George University Hospital Medical Center

    Beirut, Lebanon

  • Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Mexico

  • Instituto Nacional de Pediatria

    Mexico City, Mexico City, Mexico

  • Hospital Infantil de Mexico Federico Gomez

    Mexico City, Mexico City, Mexico

  • Russian Children Neuromuscular Center of Veltischev

    Moskva, Russia

  • Regional Pediatric Clinical Hospital #1

    Yekaterinburg, Russia

  • King Fahad Specialist Hospital

    Dammam, Saudi Arabia

  • National Guard Health Affairs: King Abdulaziz Medical City

    Jeddah, Saudi Arabia

  • King Faisal Specialist Hospital & Research Center

    Riyadh, Saudi Arabia

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Sant Joan de Deu

    Esplugues Del Llobregat, Barcelona, Spain

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.